First-Line Axi-Cel Yields Rapid Response in Large B-Cell Lymphoma

Article

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.

In phase 2 ZUMA-12 trial (NCT03761056), patients with high-risk large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated rapid and durable responses in the first-line setting with a high objective response rate of 89% and a complete response (CR) of 78%, according to a presentation given by Sattva S. Neelapu, MD, from MD Anderson Cancer Center, at the 2021 American Society of Hematology Annual Meeting.1

With a median follow-up of 17.4 months (range, 6.0-26.7), investigators found among all treated patients (n = 40) the overall response rate (ORR) to be 90% (95% CI, 76%-97%) and the complete response (CR) to be 80% (95% CI, 64%-91%). Among efficacy evaluable patients (n = 37) with a median follow-up of 15.9 months (range, 6.0-26.7), ORR was 89% (95% CI, 75%-97%) and the CR was 78% (95% CI, 62%-90%). Duration of response (DOR), progression-free survival (PFS), and event-free survival (EFS) were not reached. Median overall survival (OS) was 24.5 months.

Axi-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with relapse or refractory (R/R) LBCL and adults with R/R follicular lymphoma after at least 2 lines of systemic therapy.

Patients were enrolled and given the option to receive nonchemotherapy bridging therapy. Patients were then given conditioning chemotherapy plus axi-cel. The conditioning therapy consisted of 30 mg/m2 of fludarabine intravenously (IV) and 500 mg/m2 of cyclophosphamide IV on days –5, –4, and –3. Patients were then given a single IV of 2 × 106 of axi-cel CAR T cells/kg on day 0. To be considered eligible for ZUMA-12, patients had an IPI score of at least 3 any time before enrollment and a dynamic risk assessment, which included a positive interim PET, with a Deauville score (DS) of 4 or 5, after 2 cycles of an anti-CD20 monoclonal antibody-positive anthracycline-containing regimen. Patients must have had an ECOG score from 0 to 1.

The primary end point was CR by an investigator assessed Lugano 2014 classification,2 and its secondary end points were ORR, DOR, EFS, PFS, OS, safety, number of CAR T cells in the blood, and cytokine levels in serum.

The median age of patients was 61 years (range, 23-86) with 38% of patients over age 65. Sixty-eight percent of patients were male. Most patients (95%) had stage 3 or 4 disease. Forty-eight percent of patients had a DS of 4.

Axi-cel’s safety profile was manageable. All patients experienced any-grade adverse events (AEs) with pyrexia (100%), headache (70%), decreased neutrophil count (55%), and nausea (53%) being the most common. Grade 3 or higher AEs occurred in 85% of patients with decreased neutrophil count (53%), decreased white blood cell count (43%), decreased white blood cell count (43%) and anemia (30%) being the most common. One patient contracted COVID-19, labeled as a grade a 5 AE, but was determined to be unrelated to treatment.

Cytokine release syndrome (CRS) occurred in all patients with 8% being grade 3. The most common symptoms for CRS were pyrexia (100%), hypotension (30%), and chills (25%). Zero patients experienced grade 4 or 5 CRS.

Neurologic events (NE) occurred in 29 (73%) patients. The most common any-grade symptoms of NEs were confused state (28%), encephalopathy (25%), and tremor (25%). Grade 2 or higher NEs was seen in 38% of patients, grade 3 or higher NEs was seen in 23% of patients, 2 patients experienced a grade 4 NEs, and zero patients experience any grade 5 NEs.

The median number of CAR T cells infused was 165 × 106 (range, 95-200), and the median number of CCR7+CD45RA+ T cells infused was 105 × 106 (range, 33-254). Investigators found an association with levels of CCR7+CD45RA+ T cells in preinfusion with a favorable pharmacokinetic profile.3

Investigators concluded that axi-cel may benefit patients with high-risk LBCL who were exposed to fewer prior therapies. These results warrant further trials of axi-cel in the first line.

References

1. Neelapu S, Dickinson M, Munoz J, et al. Primary analysis of zuma-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large b-cell lymphoma (LBCL). Presented at: 2021 ASH Annual Meeting and Exposition; December 11-14, 2021; Atlanta, GA. Abstract 739

2. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119-3128. doi:10.1200/JCO.19.02104

3. Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898-4911. doi:10.1182/bloodadvances.2020002394 Abstract 739

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content